{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013785","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.908320+00:00","generated_at":"2026-05-15T08:15:33.368820+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir Pharmaceuticals submits IND to FDA for Telomir-1 in metastatic triple-negative breast cancer","bullets":["IND submitted March 31, 2026 for oral Telomir-Zn (Telomir-1) in advanced/metastatic TNBC.","Data from IND-enabling pharmacology, toxicology, and manufacturing studies included in submission.","Planned Phase 1/2 trial: 3+3 dose-escalation, then Simon two-stage with ORR as primary endpoint.","Preclinical GLP safety studies showed no treatment-related adverse or dose-limiting toxicities.","Telomir-1 reduces redox-active iron and increases zinc, inhibiting iron-dependent histone demethylases."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013785","json":"https://secwatch.observer/filing/0001493152-26-013785.json","markdown":"https://secwatch.observer/filing/0001493152-26-013785.md","text":"https://secwatch.observer/filing/0001493152-26-013785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/0001493152-26-013785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226013785/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:15:33.368820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}